logo
Plus   Neg
Share
Email

AstraZeneca Collaborating With Massachusetts General Hospital To Create Digital Health Solutions

Biopharmaceutical company AstraZeneca (AZN) announced Tuesday that it has entered into a collaboration agreement with Massachusetts General Hospital (MGH) to create digital health solutions that address today's most urgent healthcare challenges.

This novel partnership is focused on creating and clinically validating patient-centric digital health solutions and establishing a new standard of care for chronic illness management outside of a clinical setting.

This collaboration is being led by the MGH Center for Innovation in Digital Healthcare (CIDH) and will utilize AstraZeneca's new AMAZE disease management platform in studies for heart failure and asthma management.

These first two studies will pilot AMAZE in a real-world setting with the goals of improving patient engagement, care-team communication and clinical outcomes while reducing healthcare costs.

Through remote monitoring, AMAZE identifies at-risk patients and delivers insights to the clinical care team at the point of care to improve the management of complex patient populations.

Following the successful conclusion of the heart failure and asthma studies, AstraZeneca and Massachusetts General Hospital plan to expand the use of AMAZE across multiple chronic disease areas.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney World, the Orlando, Florida-based entertainment complex, is easing the health safety guidelines that were rolled out to prevent the spread of the ongoing COVID-19 pandemic. The complex is ending temperature checks in a phased manner following the advice of the Centers for Disease Control and Prevention (CDC) and local health officials. Frito-Lay North America, the convenient foods division of food and beverages giant PepsiCo, Inc., is recalling select Ruffles All Dressed Potato Chips citing the possible presence of undeclared milk ingredients, a known allergen, the U.S. Food and Drug Administration said. According to the agency, the recalled products may have distributed regionally to Walmart's Sam's Club Warehouses. Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies initiated...
Follow RTT